MedTrace Logo

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

NCT05922501 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-14

No results posted yet for this study

Summary

The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

Conditions

Interventions

DRUG

Isatuximab

An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.

DRUG

Belantamab mafodotin

An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.

DRUG

Pomalidomide

An immunomodulatory agent, capsule taken orally.

DRUG

Dexamethasone

A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Andrew Yee, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2028-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05922501 on ClinicalTrials.gov